Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific T cell therapies demonstrate clinical safety and positive clinical data across multiple...
Source: marketscreener.com